Perfusion of treatment Rituximab
Phase 3Monoclonal antibody
Perfusion of treatment Rituximab is one of 36 small molecule programs targeting Relapsing-Remitting Multiple Sclerosis. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
38 competitors in Relapsing-Remitting Multiple Sclerosis
#DrugCompanyPhaseTrials
1Gilenya
NovartisApproved
Tecfidera
BiogenApproved
Medrol
PfizerApproved
Celexa
AbbVieApproved
Calciferol
Jazz PharmaceuticalsApproved
Cytosar
TevaApproved
Actos
TakedaApproved
Zeposia
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Zocor
OOrganon and Co
Approved
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company
- RRennes University Hospital